Cyclerion Therapeutics (CYCN) Profit After Tax (2018 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Profit After Tax of -$976000.0 for Q3 2025, down 34.99% year-over-year from -$1.5 million in Q3 2024, and down 201.23% quarter-over-quarter from -$324000.0 in Q2 2025.
Cyclerion Therapeutics (CYCN) Profit After Tax (2018 - 2025) Analysis & Trends
Cyclerion Therapeutics' Profit After Tax history runs 8 years deep, the most recent figure standing at -$976000.0 for Q3 2025.
- In Q3 2025, Profit After Tax fell 34.99% year-over-year to -$976000.0; the TTM figure through Sep 2025 stood at -$2.2 million (up 58.47% YoY), while the FY2024 annual figure was -$3.1 million, up 75.72% from the prior year.
- Profit After Tax for Q3 2025 stood at -$976000.0, down from -$324000.0 in the prior quarter.
- The five-year high for Profit After Tax was $536000.0 in Q4 2024, with the low at -$16.2 million in Q2 2021.
- The 5-year median for Profit After Tax is -$4.3 million (2022), against an average of -$5.8 million.
- The sharpest annual moves came in 2022 and 2024: Profit After Tax slumped 86.63% in 2022, then surged 131.64% in 2024.
- Cyclerion Therapeutics' Profit After Tax stood at -$10.8 million in 2021, then jumped by 59.88% to -$4.3 million in 2022, then soared by 60.81% to -$1.7 million in 2023, then soared by 131.64% to $536000.0 in 2024, then sank by 282.09% to -$976000.0 in 2025.
- Business Quant data shows CYCN's Profit After Tax at -$976000.0 in Q3 2025, -$324000.0 in Q2 2025, and -$1.4 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -976,000.00 |
| Jun 30, 2025 | -324,000.00 |
| Mar 31, 2025 | -1.43 Mn |
| Dec 31, 2024 | 536,000.00 |
| Sep 30, 2024 | -723,000.00 |
| Jun 30, 2024 | -1.32 Mn |
| Mar 31, 2024 | -1.54 Mn |
| Dec 31, 2023 | -1.69 Mn |
| Sep 30, 2023 | -5.91 Mn |
| Jun 30, 2023 | -4.18 Mn |
| Mar 31, 2023 | -6.95 Mn |
| Dec 31, 2022 | -4.32 Mn |
| Sep 30, 2022 | -10.50 Mn |
| Jun 30, 2022 | -13.39 Mn |
| Mar 31, 2022 | -12.98 Mn |
| Dec 31, 2021 | -10.78 Mn |
| Sep 30, 2021 | -11.29 Mn |
| Jun 30, 2021 | -16.18 Mn |
| Mar 31, 2021 | -6.95 Mn |
| Dec 31, 2020 | -19.23 Mn |